BioSpace News Archive

The prize was awarded for their work on discovering how cells detect and respond to changes in oxygen availability, a process that is key to the survival of many cancers.

Connexient, the leader in digital wayfinding for healthcare, is pleased to announce a partnership with Royal Victoria Regional Health Centre.

SaVida Health, a leader in outpatient medication-assisted treatment for opioid and alcohol addiction, is opening a new treatment center in Morrisville, VT on October 21st

Sekisui Diagnostics announces the Acucy Influenza A&B Test has received 510(k) clearance as a Class II assay from the US Food and Drug Administration (FDA), as well as, CLIA Waiver (Clinical Laboratory Improvement Amendments) for use on the Acucy Reader.

Cohen Veterans Bioscience (CVB), a non-profit organization dedicated to advancing brain health through data driven science, and the Stanley Center for Psychiatric Research at the Broad Institute at MIT and Harvard, announce findings from a study published in Nature Communications that identifies three genome wide genetic loci associated with PTSD risk.

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its third quarter 2019 financial results on Wednesday, October 30, 2019.

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today issued its 2018/2019 Corporate Responsibility Report.

Susan G. Komen®, the world’s leading breast cancer organization, today awarded grants to three researchers who are working to better understand and address why certain populations of breast cancer patients have different outcomes, including why African-American women in the U.S. are 40 percent more likely to die from breast cancer than Caucasian women.

Biodesix, Inc. the leader in lung cancer diagnostics, today announced the appointment of internationally recognized lung cancer expert, James Jett, M.D., as Chief Medical Officer

Additional results from the Phase 3 confirmatory clinical trial (OPTIC) of teprotumumab, an investigational medicine being developed by Horizon Therapeutics plc, will be presented at the American Society of Ophthalmic Plastic and Reconstructive Surgery (ASOPRS) 50th Anniversary 2019 Fall Scientific Symposium in San Francisco on Oct. 11.